Thomas E Shenk

USPTO Granted Patents = 28 (Patent Applications = 16)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 2.8

ph-index = 10

Forward Citations = 578(Granted Patents)

Company Filing History:

Barnes Jewish Hospital

patents

Years Active: 1989-2023

Loading Chart...

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11726088 - Sirtuin 4 (SIRT4) lipoamidase activity and uses thereof (2023-08-15),

2. 11129891 - Cytomegalovirus surface protein complex for use in vaccines and as a drug target (2021-09-28),

3. 11008551 - Method to increase the infectivity of virus particles (2021-05-18),

4. 10813934 - Sirtuin modulators as inhibitors of cytomegalovirus (2020-10-27),

5. 10788492 - SIRT4 lipoamidase activity and uses thereof (2020-09-29),

6. 10300130 - Cytomegalovirus vaccines and methods of production (2019-05-28),

7. 10174290 - Method to increase the infectivity of virus particles (2019-01-08),

8. 9757407 - Treatment of viral infections by modulation of host cell metabolic pathways (2017-09-12),

9. 9439960 - Cytomegalovirus vaccines and methods of production (2016-09-13),

10. 9212349 - Method to produce virus in cultured cells (2015-12-15),

11. 9168269 - Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals (2015-10-27),

12. 9149445 - Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections (2015-10-06),

13. 9029413 - Treatment of viral infections by modulation of host cell metabolic pathways (2015-05-12),

14. 8828399 - Cytomegalovirus surface protein complex for use in vaccines and as a drug target (2014-09-09),

15. 8173362 - Cytomegalovirus surface protein complex for use in vaccines and as a drug target (2012-05-08),

Title: The Innovations of Thomas E. Shenk

Introduction

Thomas E. Shenk, a prominent inventor based in Princeton, NJ, has made significant contributions to the fields of molecular biology and virology. With a remarkable portfolio of 28 patents, his innovations have advanced our understanding of various biological processes and potential therapeutic approaches.

Latest Patents

Among his latest patents, Shenk's work on Sirtuin 4 (SIRT4) lipoamidase activity stands out. This patent outlines a method to assay pyruvate dehydrogenase complex (PDHC) activity in mammalian cells expressing human SIRT4. It involves measuring the level of a specific lipoamide peptide, which indicates how SIRT4 regulates PDHC activity through hydrolysis of lipoamide cofactors.

Another notable patent concerns immunogenic compositions for human cytomegalovirus (CMV). This patent describes the development of prophylactic and therapeutic vaccines utilizing a human CMV protein complex, specifically pUL128 or pUL130. It also details methods for creating therapeutic antibodies and screening compounds to inhibit CMV infections in various cell types.

Career Highlights

Shenk's illustrious career includes notable associations with Princeton University and The Trustees of Princeton University. His research has significantly impacted the fields of virology and cellular metabolism, paving the way for future innovations in vaccine development and therapeutic treatments.

Collaborations

Throughout his career, Shenk has collaborated with esteemed colleagues such as Dai Wang and Joshua D. Rabinowitz. These partnerships have contributed to nuanced research insights and advancements in their shared areas of expertise.

Conclusion

With a legacy marked by innovation and collaboration, Thomas E. Shenk continues to influence the scientific community through his inventions and patents. His work not only enhances our understanding of critical biological processes but also holds promise for developing future medical treatments.

This text is generated by artificial intelligence and may not be accurate.